Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,052 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors.
Mullamitha SA, Ton NC, Parker GJ, Jackson A, Julyan PJ, Roberts C, Buonaccorsi GA, Watson Y, Davies K, Cheung S, Hope L, Valle JW, Radford JA, Lawrance J, Saunders MP, Munteanu MC, Nakada MT, Nemeth JA, Davis HM, Jiao Q, Prabhakar U, Lang Z, Corringham RE, Beckman RA, Jayson GC. Mullamitha SA, et al. Among authors: cheung s. Clin Cancer Res. 2007 Apr 1;13(7):2128-35. doi: 10.1158/1078-0432.CCR-06-2779. Clin Cancer Res. 2007. PMID: 17404096 Clinical Trial.
Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume.
Jayson GC, Parker GJ, Mullamitha S, Valle JW, Saunders M, Broughton L, Lawrance J, Carrington B, Roberts C, Issa B, Buckley DL, Cheung S, Davies K, Watson Y, Zinkewich-Péotti K, Rolfe L, Jackson A. Jayson GC, et al. Among authors: cheung s. J Clin Oncol. 2005 Feb 10;23(5):973-81. doi: 10.1200/JCO.2005.01.032. Epub 2004 Oct 4. J Clin Oncol. 2005. PMID: 15466784 Clinical Trial.
Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2.
Ton NC, Parker GJ, Jackson A, Mullamitha S, Buonaccorsi GA, Roberts C, Watson Y, Davies K, Cheung S, Hope L, Power F, Lawrance J, Valle J, Saunders M, Felix R, Soranson JA, Rolfe L, Zinkewich-Peotti K, Jayson GC. Ton NC, et al. Among authors: cheung s. Clin Cancer Res. 2007 Dec 1;13(23):7113-8. doi: 10.1158/1078-0432.CCR-07-1550. Clin Cancer Res. 2007. PMID: 18056191 Clinical Trial.
Comparison of normal tissue R1 and R*2 modulation by oxygen and carbogen.
O'Connor JP, Naish JH, Jackson A, Waterton JC, Watson Y, Cheung S, Buckley DL, McGrath DM, Buonaccorsi GA, Mills SJ, Roberts C, Jayson GC, Parker GJ. O'Connor JP, et al. Among authors: cheung s. Magn Reson Med. 2009 Jan;61(1):75-83. doi: 10.1002/mrm.21815. Magn Reson Med. 2009. PMID: 19097212 Free article.
Tumour enhancing fraction (EnF) in glioma: relationship to tumour grade.
Mills SJ, Soh C, O'Connor JP, Rose CJ, Buonaccorsi GA, Cheung S, Zhao S, Parker GJ, Jackson A. Mills SJ, et al. Among authors: cheung s. Eur Radiol. 2009 Jun;19(6):1489-98. doi: 10.1007/s00330-008-1288-z. Epub 2009 Feb 7. Eur Radiol. 2009. PMID: 19198847 Free article.
2,052 results